^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
C-13-60
i
Other names: C-13-60, CEA-targeted CAR-T therapy, C1360, C 13 60
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Chongqing Precision Biotech
Drug class:
CEA-targeted CAR-T immunotherapy
Related drugs:
1m
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial. (PubMed, Nat Cancer)
The predefined safety endpoint was met. PC13 demonstrated manageable toxicity and promising efficacy, supporting further investigations.
P1 data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
C-13-60
4ms
PBC102: A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=48, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
cyclophosphamide • fludarabine IV • C-13-60
4ms
CEA CAR-T Therapy After Cytoreduction in Colorectal Cancer Patients With Peritoneal Metastases (clinicaltrials.gov)
P1, N=12, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial
|
cyclophosphamide • fludarabine IV • C-13-60
6ms
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors (clinicaltrials.gov)
P1, N=108, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial
|
cyclophosphamide • fludarabine IV • C-13-60
11ms
CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov)
P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker
|
cyclophosphamide • fludarabine IV • C-13-60
11ms
CAR-T Therapy Targeting CEA in Advanced CEA-Positive Lung Cancer (clinicaltrials.gov)
P1, N=60, Not yet recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • IO biomarker
|
cyclophosphamide • fludarabine IV • C-13-60
1year
PBC039: A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=60, Active, not recruiting, Weijia Fang, MD | Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Dec 2025
Enrollment closed • Trial completion date • IO biomarker
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
cyclophosphamide • fludarabine IV • C-13-60
1year
Study of CEA Targeting CAR-T in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=72, Recruiting, Weijia Fang, MD
New P1 trial
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
cyclophosphamide • fludarabine IV • C-13-60
1year
A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer (clinicaltrials.gov)
P1, N=48, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • IO biomarker
|
CEACAM5 positive
|
cyclophosphamide • fludarabine IV • C-13-60
over2years
Intraperitoneal administration of carcinoembryonic antigen-directed chimeric antigen receptor T cells is a robust delivery route for effective treatment of peritoneal carcinomatosis from colorectal cancer in pre-clinical study. (PubMed, Cytotherapy)
Taken together, our data suggest that i.p. administration of CAR T cells may be a robust delivery route for effective treatment of cancer.
Preclinical • Journal • CAR T-Cell Therapy
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • PSCA (Prostate Stem Cell Antigen 2)
|
C-13-60
over2years
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=36, Recruiting, Chongqing Precision Biotech Co., Ltd | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
CEACAM5 expression • CEACAM5 positive
|
cyclophosphamide • C-13-60
over2years
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=60, Recruiting, Chongqing Precision Biotech Co., Ltd
New P1 trial • Metastases
|
CEACAM5 positive
|
cyclophosphamide • C-13-60
Share via
